185 related articles for article (PubMed ID: 12079501)
1. Enzyme replacement reverses abnormal cerebrovascular responses in Fabry disease.
Moore DF; Altarescu G; Herscovitch P; Schiffmann R
BMC Neurol; 2002 Jun; 2():4. PubMed ID: 12079501
[TBL] [Abstract][Full Text] [Related]
2. Elevated cerebral blood flow velocities in Fabry disease with reversal after enzyme replacement.
Moore DF; Altarescu G; Ling GS; Jeffries N; Frei KP; Weibel T; Charria-Ortiz G; Ferri R; Arai AE; Brady RO; Schiffmann R
Stroke; 2002 Feb; 33(2):525-31. PubMed ID: 11823664
[TBL] [Abstract][Full Text] [Related]
3. The effect of acetazolamide on the changes of cerebral blood flow and oxygen metabolism during visual stimulation.
Yamauchi H; Okazawa H; Kishibe Y; Sugimoto K; Takahashi M
Neuroimage; 2003 Sep; 20(1):543-9. PubMed ID: 14527614
[TBL] [Abstract][Full Text] [Related]
4. Agalsidase alfa: a review of its use in the management of Fabry disease.
Keating GM
BioDrugs; 2012 Oct; 26(5):335-54. PubMed ID: 22946754
[TBL] [Abstract][Full Text] [Related]
5. PET study of greater visual activation in schizophrenia.
Taylor SF; Tandon R; Koeppe RA
Am J Psychiatry; 1997 Sep; 154(9):1296-8. PubMed ID: 9286192
[TBL] [Abstract][Full Text] [Related]
6. Enzyme replacement therapy in Fabry disease: a randomized controlled trial.
Schiffmann R; Kopp JB; Austin HA; Sabnis S; Moore DF; Weibel T; Balow JE; Brady RO
JAMA; 2001 Jun; 285(21):2743-9. PubMed ID: 11386930
[TBL] [Abstract][Full Text] [Related]
7. Relationship between vasodilatation and cerebral blood flow increase in impaired hemodynamics: a PET study with the acetazolamide test in cerebrovascular disease.
Okazawa H; Yamauchi H; Toyoda H; Sugimoto K; Fujibayashi Y; Yonekura Y
J Nucl Med; 2003 Dec; 44(12):1875-83. PubMed ID: 14660711
[TBL] [Abstract][Full Text] [Related]
8. Cerebellar vascular response to acetazolamide in crossed cerebellar diaschisis: a comparison of 99mTc-HMPAO single-photon emission tomography with 15O-H2O positron emission tomography.
Kuwabara Y; Ichiya Y; Sasaki M; Akashi Y; Yoshida T; Fukumura T; Masuda K
Eur J Nucl Med; 1996 Jun; 23(6):683-9. PubMed ID: 8662103
[TBL] [Abstract][Full Text] [Related]
9. Xenon effects on regional cerebral blood flow assessed by 15O-H2O positron emission tomography: implications for hyperpolarized xenon MRI.
Liotti M; Martin CC; Gao JH; Roby JW; Mayberg HS; Zamarripa F; Jerabek PA; Fox PT
J Magn Reson Imaging; 1997; 7(4):761-4. PubMed ID: 9243399
[TBL] [Abstract][Full Text] [Related]
10. Regional cerebral hyperperfusion and nitric oxide pathway dysregulation in Fabry disease: reversal by enzyme replacement therapy.
Moore DF; Scott LT; Gladwin MT; Altarescu G; Kaneski C; Suzuki K; Pease-Fye M; Ferri R; Brady RO; Herscovitch P; Schiffmann R
Circulation; 2001 Sep; 104(13):1506-12. PubMed ID: 11571244
[TBL] [Abstract][Full Text] [Related]
11. Quantitative measurement of regional cerebrovascular reactivity to acetazolamide using 123I-N-isopropyl-p-iodoamphetamine autoradiography with SPECT: validation study using H2 15O with PET.
Ogasawara K; Ito H; Sasoh M; Okuguchi T; Kobayashi M; Yukawa H; Terasaki K; Ogawa A
J Nucl Med; 2003 Apr; 44(4):520-5. PubMed ID: 12679394
[TBL] [Abstract][Full Text] [Related]
12. Enzyme replacement therapy improves peripheral nerve and sweat function in Fabry disease.
Schiffmann R; Floeter MK; Dambrosia JM; Gupta S; Moore DF; Sharabi Y; Khurana RK; Brady RO
Muscle Nerve; 2003 Dec; 28(6):703-10. PubMed ID: 14639584
[TBL] [Abstract][Full Text] [Related]
13. Agalsidase-beta therapy for advanced Fabry disease: a randomized trial.
Banikazemi M; Bultas J; Waldek S; Wilcox WR; Whitley CB; McDonald M; Finkel R; Packman S; Bichet DG; Warnock DG; Desnick RJ;
Ann Intern Med; 2007 Jan; 146(2):77-86. PubMed ID: 17179052
[TBL] [Abstract][Full Text] [Related]
14. Time dependency of the acetazolamide effect on cerebral hemodynamics in patients with chronic occlusive cerebral arteries. Early steal phenomenon demonstrated by [15O]H2O positron emission tomography.
Kuwabara Y; Ichiya Y; Sasaki M; Yoshida T; Masuda K
Stroke; 1995 Oct; 26(10):1825-9. PubMed ID: 7570733
[TBL] [Abstract][Full Text] [Related]
15. Long-term prognosis of medically treated patients with internal carotid or middle cerebral artery occlusion: can acetazolamide test predict it?
Kuroda S; Houkin K; Kamiyama H; Mitsumori K; Iwasaki Y; Abe H
Stroke; 2001 Sep; 32(9):2110-6. PubMed ID: 11546904
[TBL] [Abstract][Full Text] [Related]
16. Effects of acetazolamide on cerebral blood flow, blood volume, and oxygen metabolism: a positron emission tomography study with healthy volunteers.
Okazawa H; Yamauchi H; Sugimoto K; Toyoda H; Kishibe Y; Takahashi M
J Cereb Blood Flow Metab; 2001 Dec; 21(12):1472-9. PubMed ID: 11740209
[TBL] [Abstract][Full Text] [Related]
17. Selective arterial distribution of cerebral hyperperfusion in Fabry disease.
Moore DF; Herscovitch P; Schiffmann R
J Neuroimaging; 2001 Jul; 11(3):303-7. PubMed ID: 11462299
[TBL] [Abstract][Full Text] [Related]
18. Differences in vasodilatory capacity and changes in cerebral blood flow induced by acetazolamide in patients with cerebrovascular disease.
Okazawa H; Yamauchi H; Sugimoto K; Takahashi M
J Nucl Med; 2003 Sep; 44(9):1371-8. PubMed ID: 12960179
[TBL] [Abstract][Full Text] [Related]
19. Cerebral blood flow in patients with Fabry disease as measured by Doppler sonography is not different from that in healthy individuals and is unaffected by treatment.
Uçeyler N; He L; Kahn AK; Breunig F; Müllges W; Sommer C
J Ultrasound Med; 2012 Mar; 31(3):463-8. PubMed ID: 22368137
[TBL] [Abstract][Full Text] [Related]
20. Fabry disease.
Germain DP
Orphanet J Rare Dis; 2010 Nov; 5():30. PubMed ID: 21092187
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
